PACB (44) CTKB (45) BRKR (59) BIO (66) ⌘ Pro Terminal →

Alamar Biosciences Inc. (ALMR) — RQD Stock Rating Cockpit

$30.60 -10.11% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $29.99

Alamar Biosciences Inc. (ALMR) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $2.36B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ALMR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ALMR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Alamar Biosciences Inc. (NASDAQ: ALMR) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $30.60 (-10.11% 1D, market cap $2.36B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ALMR compare to PACB and CTKB in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), ALMR carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PACB (Pacific Biosciences of California Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $901.4M) and CTKB (Cytek Biosciences Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -12.7%, cap $818.9M). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while BRKR leads on capital efficiency (1.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ALMR?

▼

Per ALMR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002104204), Alamar Biosciences Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $140.0M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $29.98 (-2.01%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 1.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+1.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALMR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (61/100 Composite)

🔍 WHY ALMR SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (21% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$24.24+8.5% Next Q

Q2 (-2Q)

Grade C$26.30+15.6% Next Q

Q3 (-1Q)

Grade C$30.39+0.7% Next Q

Current

Grade C-$30.60+0.5% Hist 90D α

Trajectory: C- (53) → C- (61)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ALMR Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 61/100 (C-) score, ALMR faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($30.64) or 200D SMA ($26.98) invalidates the momentum regime and cuts Target Base ($31.01) toward Bear Floor ($24.19).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALMR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ALMR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 61%NO 39%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

57.530 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE57% OF RANGE

L: $19$30.60H: $40

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 10 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: CRQD 25 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 26 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on ALMR

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (50)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (63)

25/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like ALMR

✓Big institutional funds and options desks are actively positioning on the bullish side.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (ALMR Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ALMR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +28.79%▲ ASCENDING CHANNEL

2026-11-02O $34.30H $34.30L $30.60C $30.60VOL 496.2K

RES: $40.13SUP: $23.53SMA50: $30.64SMA200: $26.98

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALMR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALMR Butterfly Map → + Track ALMR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ALMR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALMR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ALMR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALMR)

Health Care Rank #169 of 1016 ⚔️ PACB vs ALMR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALMR vs. PACB, CTKB, BRKR, BIO)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Alamar Biosciences Inc. (ALMR) ranks #169 by composite RQD confidence (61/100, grade C-) and #230 by equity capitalization ($2.36B). Within this direct 5-issuer industry benchmark cohort, BIO leads on earnings valuation at 13.5x trailing P/E, while BRKR leads on capital efficiency and profitability with 1.3% ROIC and 45.9% gross margin. BIO currently holds the highest overall quantitative score in the immediate peer group at 66/100 (C+) compared with ALMR at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ALMR ACTIVE Alamar Biosciences Inc.	C-	61/100	—	—	—	-10.11%	$2.36B	Benchmark Subject
PACB Pacific Biosciences of California Inc.	D	44/100	—	28.6%	-35.0%	-10.17%	$901.4M	/pacb-vs-almr →
CTKB Cytek Biosciences Inc.	D	45/100	—	51.8%	-12.7%	-2.70%	$818.9M	/ctkb-vs-almr →
BRKR Bruker Corporation	C-	59/100	—	45.9%	1.3%	-7.95%	$9.45B	/brkr-vs-almr →
BIO Bio-Rad Laboratories Inc.	C+	66/100	13.5x	51.9%	0.5%	-3.18%	$10.28B	/bio-vs-almr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002104204

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Alamar Biosciences Inc. (ALMR) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, ALMR closed FY2025 with $140.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$140.0M	—

3. ALMR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALMR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ALMR compare to PACB and CTKB in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ALMR?

Where is ALMR trading relative to its 50-day, 200-day, and 52-week technical levels?

ALMR last traded at $30.60 (-10.11% on volume of 740,095 shares), positioning the stock -0.13% below its 50-day simple moving average ($30.64) and +13.42% above its 200-day simple moving average ($26.98). Across its 52-week range of $18.85 to $39.61, ALMR sits at the 56.6% percentile with a 14-day RSI of 57.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($26.77 to $34.43).

ALMR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ALMR stock right now?

Alamar Biosciences Inc. (ALMR) currently earns a Roarable Rating of C- (Hold — HOLD) with 61/100 RQD Confidence. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.

What is ALMR's 12-month price target and RQD AI Jury consensus?

ALMR's 12-month base price target is $31.01 (range $24.19 to $41.59), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ALMR RQD Cockpit ALMR 12M Forecast ALMR Earnings & Move ALMR Dividends & DRIP ALMR Insiders & 13F ALMR Whale Options ALMR Profit Sankey ALMR News & Why

ROARABLE RATING BRIEF • RQD 61/100 (C-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ALMR — Alamar Biosciences Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:12:29Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ALMR scores 61 out of 100, a letter grade of C-, with a verdict label of "Roarable Hold — Cautious Neutral." The fundamental cash engine pillar scores 10 out of 20, reflecting ROIC of 0% and FCF yield of 0%; for a prospective investor, this means the source data shows no measurable cash return on invested capital today, so the investment case does not currently rest on earnings or cash generation. The whale and 13F flow pillar scores 16 out of 20, citing institutional accumulation and options positioning, which is the strongest pillar and suggests institutional interest is a meaningful upside driver. The insider conviction pillar scores 9 out of 20, based on SEC Form 4 and Congressional PTR cluster flow, indicating weaker insider signal support. The macro regime fit pillar scores 13 out of 20, with beta of 1.0 and sector sensitivity, meaning the stock is rated as moving in line with the broader market. The forensic balance sheet pillar scores 13 out of 20, citing Altman Z of 2.5, Piotroski F of 6 out of 9, and Debt/Equity of 0.5, which points to a moderately sound balance sheet. Valuation tradeoffs are significant: with no reported earnings-based multiples available, investors are paying for future outcomes rather than current cash flows, and the 52-week range of $18.85 to $39.61 against a price of $34.04 shows the stock has moved widely within the year. This analysis is educational and not personalized financial advice.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025 (filed 2025-12-31)	$0.0M	$0.0M	$0.0M	N/A	N/A	$30.0M	N/A

Per the SEC financials, reported revenue, operating income, and net income for FY 2025 are each $0.0M, and gross, operating, and net margins are each 0%. ROIC is 0% and FCF yield is 0% per the market data. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 6 out of 9, with Debt/Equity of 0.5. Reported cash is $30.0M, while debt is listed as N/A in the financials, so the balance sheet posture cannot be fully characterized from the source data.

Recent Catalysts & News Wire Analysis

Recent items in the news feed include a Yahoo Finance Singapore market report, a Seeking Alpha piece titled "Alamar: The Consumables Flywheel Is Just Getting Started," a Moomoo report of a 10% shareholder selling US$8.57 Million in Common Stock, a Stock Titan report that a former CEO of a cancer-detection company joined the board, a GuruFocus Q3 2026 earnings preview, and a MarketBeat report of a major shareholder selling $4,812,181.01 in stock. Per the news wire, all items carry a YELLOW light and MARKET WIRE impact label. Watch items include the reported shareholder sales, which appear in two separate news items. The Butterfly Supply-Chain Graph reports a LIQUIDITY_TAILWIND signal with a BULLISH direction and severity score of 94, a macro tailwind score of 96/100, and a 3.56x net liquidity elasticity with r = -0.18, which the graph itself frames as a rolling 5-year regression result. The graph also cites a Net Liquidity Index of $5,745.73B with a 4-week rate of change of -0.64%.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE and no butterfly links are reported. Upstream and downstream dependencies are not available in source data. Sector correlations beyond the liquidity sensitivity figure are not available in source data. The main second-order channel the source data identifies is liquidity: because the graph reports a 3.56x net liquidity beta, shifts in Fed balance sheet, Treasury General Account, and overnight RRP conditions could amplify ALMR's price moves relative to the broader market. Investors should watch whether liquidity conditions remain supportive, since the graph's bullish signal depends on them.

Open Questions

What products and services does Alamar Biosciences sell, and who are its customers?
Why are FY 2025 revenue and net income reported as $0.0M, and what is the company's current revenue trajectory?
What is the company's debt level, given debt is listed as N/A while Debt/Equity is 0.5?
What are the identities and sizes of the shareholder sales reported in recent news, and how do they relate to insider conviction?
What are the specific drivers behind the institutional accumulation credited in the whale and 13F flow pillar?

ALMR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Alamar Biosciences Inc. (ALMR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ALMR Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance Singapore • 9h ago

Alamar Biosciences, Inc. (ALMR) stock price, news, quote and history

Yahoo Finance Singapore report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 12h ago

Alamar: The Consumables Flywheel Is Just Getting Started (NASDAQ:ALMR)

Seeking Alpha report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 15h ago

Alamar Biosciences(ALMR.US) 10% Shareholder Sells US$8.57 Million in Common Stock

Moomoo report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 18h ago

A former CEO of a cancer-detection company joins Alamar's board.

Stock Titan report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 21h ago

Alamar Biosciences Inc (ALMR) Q3 2026 Earnings Report Preview: W

GuruFocus report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Sells $4,812,181.01 in Stock

MarketBeat report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026

Yahoo Finance report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 1d ago

Alamar Biosciences (ALMR) Highlights Breakthrough ALS Protein Si

GuruFocus report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ALMR Bull vs. Bear Conversation Board — What's Your Call at $30.60?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ALMR 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $36.76 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ALMR (C- • RQD 61/100) a Buy at $34.04?

Welcome to the ALMR (Alamar Biosciences Inc.) Roar Pit. Current RQD Composite is 61/100 (Roarable Hold — Cautious Neutral) in Biotechnology: Laboratory Analytical Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $25.87 (-24.0%)

Spot @ $34.04

Pump the brakes on ALMR — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ALMR, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Alamar Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $39.83 (+17.0%)

Spot @ $34.04

ALMR cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ALMR, the market is fixating on short-term headline noise in Biotechnology: Laboratory Analytical Instruments and ignoring the balance sheet and cash flow trajectory. At $34.04 (52-wk range $18.85 - $39.61), any beat on forward guidance forces shorts and underweight funds to chase.